Special Issue

Topic: Clinical Use of Circulating Nucleic Acids in Bodily Fluids: Noninvasive Prenatal Testing, Oncology, Transplant Monitoring and Beyond

A Special Issue of Extracellular Vesicles and Circulating Nucleic Acids

ISSN 2767-6641 (Online)

Submission deadline: 1 May 2022

Guest Editor(s)

Erik Sistermans

Professor, Department of Clinical Genetics, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Peiyong Jiang

Assistant Professor, Chinese University of Hong Kong, Shatin, Hong Kong, China.

Special Issue Introduction

The discovery of circulating cell-free fetal DNA in maternal plasma has made a paradigm shift in noninvasive prenatal testing (NIPT), rapidly being translated into clinical practices worldwide, for example, cell-free DNA(cfDNA) based fetal chromosomal aneuploidy detection and diagnosis of monogenic diseases. Recently, many efforts have been made in expanding the success of cfDNA-based NIPT to different clinical scenarios, such as oncology and organ transplantation. CfDNA is illustrated to be non-randomly fragmented and released from multiple tissues within the body.  Genetics, epigenetics, and fragmentomics of cfDNA open up many possibilities for developing novel diagnostic tools. For instance, the use of genetics of cfDNA allows for noninvasive prenatal testing for signal gene disorders such as cystic fibrosis, alpha- and beta-thalassemias, sickle cell anemia, fragile X syndrome, etc. The use of epigenetics of cfDNA (e.g., DNA methylation) is an important means for deciphering the tissues of origin of cfDNA. The fragmentomics of cfDNA, such as fragment sizes, endpoints, end motifs, jagged ends, and nucleosome profiles, is an emergent area for clinical biomarker development.

This Special Issue aims to cover  cfDNA-related research articles, reviews, and perspectives, including but not limited to the topics highlighted below:
● Noninvasive prenatal testing;
● Cancer detection and monitoring;
● Organ transplant monitoring;
● Organ damage assessment (e.g., trauma, and autoimmune diseases).

Submission Deadline

1 May 2022

Submission Information

For Author Instructions, please refer to https://oaepublish.com/evcna/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=evcna&SpecialIssueId=803
Submission Deadline: 1 May 2022
Contacts: Margie Ma, Managing Editor, margie@oaepublish.com

Published Articles

Open Access Review

Non-invasive prenatal diagnosis (NIPD): current and emerging technologies

Extracell Vesicles Circ Nucleic Acids 2023;4:3-26.
DOI: 10.20517/evcna.2022.44
Available online: 21 Feb 2023
Open Access Review

Emerging frontiers of cell-free DNA fragmentomics

Extracell Vesicles Circ Nucleic Acids 2022;3:380-92.
DOI: 10.20517/evcna.2022.34
Available online: 20 Dec 2022
Open Access Review

Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility

Extracell Vesicles Circ Nucleic Acids 2022;3:216-34.
DOI: 10.20517/evcna.2022.21
Available online: 9 Aug 2022
Open Access Review

Cell-free DNA as a biomarker in cancer

Extracell Vesicles Circ Nucleic Acids 2022;3:195-215.
DOI: 10.20517/evcna.2022.20
Available online: 1 Aug 2022
Extracellular Vesicles and Circulating Nucleic Acids
ISSN 2767-6641 (Online)
Follow Us


All published articles are preserved here permanently:



All published articles are preserved here permanently: